Pediatrix Medical Group, Inc. $MD Holdings Lifted by American Century Companies Inc.

American Century Companies Inc. grew its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 38.9% in the third quarter, according to its most recent filing with the SEC. The firm owned 2,682,976 shares of the company’s stock after acquiring an additional 751,109 shares during the quarter. American Century Companies Inc. owned about 3.12% of Pediatrix Medical Group worth $44,940,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of MD. Y Intercept Hong Kong Ltd acquired a new position in shares of Pediatrix Medical Group during the 3rd quarter valued at $513,000. Dana Investment Advisors Inc. lifted its holdings in shares of Pediatrix Medical Group by 5.6% in the third quarter. Dana Investment Advisors Inc. now owns 801,462 shares of the company’s stock valued at $13,424,000 after buying an additional 42,162 shares during the period. Allianz Asset Management GmbH boosted its stake in Pediatrix Medical Group by 158.5% during the third quarter. Allianz Asset Management GmbH now owns 158,777 shares of the company’s stock valued at $2,660,000 after buying an additional 97,365 shares in the last quarter. Hsbc Holdings PLC boosted its stake in Pediatrix Medical Group by 226.6% during the second quarter. Hsbc Holdings PLC now owns 111,997 shares of the company’s stock valued at $1,591,000 after buying an additional 77,704 shares in the last quarter. Finally, Edgestream Partners L.P. acquired a new position in Pediatrix Medical Group during the second quarter worth about $763,000. Institutional investors own 97.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Truist Financial reduced their target price on shares of Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating for the company in a report on Thursday, February 19th. UBS Group dropped their price target on Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating on the stock in a report on Tuesday, February 24th. Zacks Research lowered Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 23rd. Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Monday, December 29th. Finally, Deutsche Bank Aktiengesellschaft set a $19.00 target price on Pediatrix Medical Group in a report on Friday, February 20th. One equities research analyst has rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $19.80.

Insider Buying and Selling at Pediatrix Medical Group

In other Pediatrix Medical Group news, CEO Mark S. Ordan sold 23,000 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $22.41, for a total value of $515,430.00. Following the completion of the sale, the chief executive officer owned 302,805 shares in the company, valued at approximately $6,785,860.05. This trade represents a 7.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.90% of the company’s stock.

Pediatrix Medical Group Stock Up 2.6%

MD stock opened at $19.79 on Friday. The business’s 50-day simple moving average is $21.11 and its 200 day simple moving average is $19.90. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.66. Pediatrix Medical Group, Inc. has a twelve month low of $11.84 and a twelve month high of $24.99. The company has a market cap of $1.64 billion, a PE ratio of 10.20 and a beta of 0.79.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings results on Thursday, February 19th. The company reported $0.50 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.53 by ($0.03). Pediatrix Medical Group had a net margin of 8.64% and a return on equity of 19.59%. The business had revenue of $493.77 million during the quarter, compared to the consensus estimate of $486.23 million. During the same period last year, the firm earned $0.51 EPS. The company’s quarterly revenue was down 1.7% compared to the same quarter last year. On average, research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.